Is Pharmacogenetic Panel Testing Applicable to Low-Dose Methotrexate in Rheumatoid Arthritis? – A Case Report

Purpose Pharmacogenetic (PGx) panel testing could help to determine the heritable component of a rheumatoid arthritis (RA) patient’s susceptibility for therapy failure and/or adverse drug reactions (ADRs) from methotrexate (MTX). Considering the literature mentioning the potential applicability of PGx panel testing within MTX regimens, we discuss the case of a patient who was treated with MTX, suffered from ADRs, and obtained a reactive PGx panel testing. Genotyping We used a commercial PGx panel test involving the ABC-transporters P-glycoprotein (P-gp; gene: ABCB1), and breast cancer resistance protein (BCRP; gene: ABCG2), the solute carriers reduced folate carrier 1 (RFC1; gene: SLC19A1), and organic anion transporting polypeptide 1B1 (OATP1B1; gene: SLCO1B1), and the enzymes inosine triphosphatase (ITPA), and glutathione transferase P1 (GSTP1). In addition, we genotyped the patient for the enzymes 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase (AICAR)/inosine monophosphate (IMP) cyclohydrolase (gene name: ATIC), gamma-glutamyl hydrolase (gene name: GGH) and methylenetetrahydrofolate reductase (gene name: MTHFR). Results The PGx profile of the patient revealed genetic variants in SLC19A1, ABCB1, and MTHFR, which may explain the ADRs experienced during the treatment with MTX and a potentially lower efficacy of MTX. Based on our interpretation of the PGx profile, we recommended the patient to avoid MTX in the future. Conclusion The MTX pathway is complex, which makes the interpretation of genetic variants affecting metabolism challenging. A reactive PGx panel test was applicable to explain ADRs experienced during MTX treatment for a patient with RA. However, the clinical utility of PGx-guided MTX treatment in a primary care setting is still limited. In order to base a recommendation for MTX on PGx data, we need genome-wide association studies, large prospective multicenter studies and PGx studies, which analyze different multi-gene haplotypes and gene-drug-drug interactions for MTX.

• Publication year

  2022

• Venue

  Pharmacogenomics and Personalized Medicine

• Publication date

  2022-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.2147/PGPM.S354011PMID 35586477PMCID 9109898
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Methotrexate

  2022cited by this paper
• Good response to methotrexate is associated with a decrease in the gene expression of ABCG2, a drug transporter, in patients with rheumatoid arthritis

  2021cited by this paper
• Polymorphisms within methotrexate pathway genes: Relationship between plasma methotrexate levels, toxicity experienced and outcome in pediatric acute lymphoblastic leukemia

  2020cited by this paper
• Pharmacogenetic information in Swiss drug labels – a systematic analysis

  2020cited by this paper
• The evolution in our understanding of the genetics of rheumatoid arthritis and the impact on novel drug discovery

  2020cited by this paper
• Predictive genetic biomarkers for the efficacy of methotrexate in rheumatoid arthritis: a systematic review

  2019cited by this paper
• S2e-Leitlinie „Therapie der rheumatoiden Arthritis mit krankheitsmodifizierenden Medikamenten“ – Was ist neu?

  2019cited by this paper
• Methotrexate pharmacogenetics in the treatment of rheumatoid arthritis.

  2019cited by this paper
• Methotrexate an Old Drug with New Tricks

  2019influential reference
• S2e-Leitlinie: Therapie der rheumatoiden Arthritis mit krankheitsmodifizierenden Medikamenten

  2018cited by this paper
• Clinical Pharmacogenetic Models of Treatment Response to Methotrexate Monotherapy in Slovenian and Serbian Rheumatoid Arthritis Patients: Differences in Patient's Management May Preclude Generalization of the Models

  2018cited by this paper
• Relationship Between Polymorphisms in Methotrexate Pathway Genes and Outcome of Methotrexate Treatment in a Cohort of 119 Patients with Juvenile Idiopathic Arthritis

  2017cited by this paper
• Clinical–pharmacogenetic predictive models for MTX discontinuation due to adverse events in rheumatoid arthritis

  2016cited by this paper
• 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis

  2016cited by this paper
• American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis

  2015influential reference
• Associations between single-nucleotide polymorphisms of RFC-1, GGH, MTHFR , TYMS, and TCII genes and the efficacy and toxicity of methotrexate treatment in patients with rheumatoid arthritis.

  2015influential reference
• Multidrug resistance 1 (MDR1) 3435C>T gene polymorphism influences the clinical phenotype and methotrexate-induced adverse events in South Indian Tamil rheumatoid arthritis

  2015cited by this paper
• Association of MDR1 C3435T and RFC1 G80A polymorphisms with methotrexate toxicity and response in Jordanian rheumatoid arthritis patients.

  2014cited by this paper
• Genetics, Epigenetics, and Regulation of Drug‐Metabolizing Cytochrome P450 Enzymes

  2014cited by this paper
• SLC19A1, SLC46A1 and SLCO1B1 polymorphisms as predictors of methotrexate-related toxicity in Portuguese rheumatoid arthritis patients.

  2014cited by this paper
• Methotrexate pharmacogenetics in rheumatoid arthritis: a status report.

  2013cited by this paper
• Genetic polymorphisms in metabolic and cellular transport pathway of methotrexate impact clinical outcome of methotrexate monotherapy in Japanese patients with rheumatoid arthritis.

  2012cited by this paper
• Pharmacogenetic Polymorphisms Contributing to Toxicity Induced by Methotrexate in the Southern Spanish Population with Rheumatoid Arthritis

  2012cited by this paper
• PharmGKB summary: methotrexate pathway.

  2011cited by this paper
• Polymorphisms C677T and A1298C in the MTHFR gene in Mexican patients with rheumatoid arthritis treated with methotrexate: implication with elevation of transaminases

  2011cited by this paper
• Polymorphisms within the folate pathway predict folate concentrations but are not associated with disease activity in rheumatoid arthritis patients on methotrexate

  2010cited by this paper
• The environment, geo-epidemiology, and autoimmune disease: Rheumatoid arthritis.

  2010cited by this paper
• Genetic polymorphisms in folate pathway enzymes as a possible marker for predicting the outcome of methotrexate therapy in Japanese patients with rheumatoid arthritis

  2009influential reference
• Methotrexate Pharmacokinetics in Transgenic Mice with Liver-Specific Expression of Human Organic Anion-Transporting Polypeptide 1B1 (SLCO1B1)

  2009cited by this paper
• Hepatic OATP1B transporters and nuclear receptors PXR and CAR: interplay, regulation of drug disposition genes, and single nucleotide polymorphisms.

  2009cited by this paper
• Gene–gene interactions in folate and adenosine biosynthesis pathways affect methotrexate efficacy and tolerability in rheumatoid arthritis

  2009influential reference
• Development and validation of a composite disease activity score for juvenile idiopathic arthritis.

  2009cited by this paper
• Methotrexate (MTX) pathway gene polymorphisms and their effects on MTX toxicity in Caucasian and African American patients with rheumatoid arthritis.

  2008cited by this paper
• Genetic variation in efflux transporters influences outcome to methotrexate therapy in patients with psoriasis.

  2008cited by this paper
• Time to treatment as an important factor for the response to methotrexate in juvenile idiopathic arthritis

  2008cited by this paper
• Reduced folate carrier-1 80G>A polymorphism affects methotrexate treatment outcome in rheumatoid arthritis

  2007cited by this paper
• ATP-binding cassette, subfamily G (ABCG family)

  2007cited by this paper
• Ancestry and pharmacogenetics of antileukemic drug toxicity.

  2007cited by this paper
• Genetic polymorphisms associated with adverse events and elimination of methotrexate in childhood acute lymphoblastic leukemia and malignant lymphoma

  2006cited by this paper
• Methotrexate pharmacogenetics: the first step toward individualized therapy in rheumatoid arthritis.

  2006cited by this paper
• Risk genotypes in folate-dependent enzymes and their association with methotrexate-related side effects in rheumatoid arthritis.

  2006cited by this paper
• Cost-effectiveness analysis of MTHFR polymorphism screening by polymerase chain reaction in Korean patients with rheumatoid arthritis receiving methotrexate.

  2006cited by this paper
• Efficacy and toxicity of methotrexate in early rheumatoid arthritis are associated with single-nucleotide polymorphisms in genes coding for folate pathway enzymes.

  2006cited by this paper
• Relationship between genetic variants in the adenosine pathway and outcome of methotrexate treatment in patients with recent-onset rheumatoid arthritis.

  2006influential reference
• ABCB1 C3435T polymorphism influences methotrexate sensitivity in rheumatoid arthritis patients.

  2006cited by this paper
• Contribution of common polymorphisms in reduced folate carrier and gamma-glutamylhydrolase to methotrexate polyglutamate levels in patients with rheumatoid arthritis.

  2004influential reference
• Polyglutamation of methotrexate with common polymorphisms in reduced folate carrier, aminoimidazole carboxamide ribonucleotide transformylase, and thymidylate synthase are associated with methotrexate effects in rheumatoid arthritis.

  2004cited by this paper
• A polymorphism (80G->A) in the reduced folate carrier gene and its associations with folate status and homocysteinemia.

  2000cited by this paper
• Influence of sulphasalazine, methotrexate, and the combination of both on plasma homocysteine concentrations in patients with rheumatoid arthritis

  1999cited by this paper
• P-glycoprotein confers methotrexate resistance in 3T6 cells with deficient carrier-mediated methotrexate uptake.

  1996cited by this paper
• The treatment of rheumatoid arthritis.

  1949cited by this paper

• HLA DRB1*01 and *04 Predisposition to Rheumatoid Arthritis and Polymorphisms of the SLCO1B1, MTHFR and PNPLA3 Genes Are Not Associated with Fatty Liver and Hepatotoxicity.

  2026cites this paper
• Genotyping of Patients with Adverse Drug Reaction or Therapy Failure: Database Analysis of a Pharmacogenetics Case Series Study

  2023cites this paper
• ABCC1, ABCG2 and FOXP3: Predictive Biomarkers of Toxicity from Methotrexate Treatment in Patients Diagnosed with Moderate-to-Severe Psoriasis

  2023cites this paper
• A Guide to a Pharmacist-Led Pharmacogenetic Testing and Counselling Service in an Interprofessional Healthcare Setting

  2022cites this paper